

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1 (currently amended): A ~~use of an effective amount of an agent that inhibits porcine fgl2 to inhibit or suppress~~ method of inhibiting or suppressing an immune response to a porcine organ or tissue comprising administering an effective amount of an agent that inhibits porcine fgl2 to the porcine organ or tissue, porcine donor or transplant recipient.

Claim 2 (currently amended): A ~~use of an effective amount of an agent that inhibits porcine fgl2 to inhibit or prevent~~ method of inhibiting or preventing thrombosis associated with xenotransplant rejection of a porcine organ or tissue comprising administering an effective amount of an agent that inhibits porcine fgl2 to the porcine organ or tissue, porcine donor or transplant recipient.

Claim 3 (currently amended): A ~~use~~ method according to claim 1 ~~or 2~~ wherein the agent is an antibody that binds to porcine fgl2.

Claim 4 (currently amended): A ~~use~~ method according to claim 1 ~~or 2~~ wherein the agent is an antisense oligonucleotide that is complementary to the porcine fgl2 sequence.

Claim 5 (currently amended): A ~~use~~ method according to ~~any one of claims 1 to 4~~ wherein the agent inhibits the porcine fgl2 having a nucleic acid sequence shown in Figure 1A (SEQ ID NO:1) or a homolog or analog thereof or inhibits a porcine fgl2 protein having an amino acid sequence show in Figure 1B (SEQ ID NO:2) or an analog, homolog or fragment thereof.

Claim 6 (currently amended): A ~~use of an~~ method according to claim 1 wherein the organ or tissue is from a transgenic pig lacking expression of the porcine fgl2 gene ~~in a xenotransplant.~~

Claim 7 (currently amended): A ~~use of an effective amount of a porcine fgl2 nucleic acid sequence, a porcine fgl2 protein or a porcine fgl2 modulator to modulate~~ method of modulating

an immune response comprising administering an effective amount of a porcine fgl2 nucleic acid sequence, a porcine fgl2 protein or a porcine fgl2 modulator to an animal in need thereof.

Claim 8 (currently amended): A ~~use~~-method according to claim 7 to modulate an immune response involved in graft rejection.

Claim 9 (currently amended); A ~~use~~-method according to claim 7 to modulate an immune response involved in fetal loss.

Claim 10 (currently amended): A ~~use~~-method according to claim 7 to modulate an immune response involved in a viral infection.

Claim 11 (currently amended): A ~~use~~-method according to claim 7 to modulate an immune response involved in a hepatitis-like disease.

Claim 12 (currently amended); A ~~use~~-method according to ~~any one of claims 7 to 14~~ wherein the porcine fgl2 has the nucleic acid sequence shown in Figure 1A (SEQ ID NO:1) or a homolog or analog thereof or an amino acid sequence shown in Figure 1B (SEQ ID NO:2) or an analog, homolog or fragment thereof.

Claim 13 (currently amended): A ~~use~~-method according to ~~any one of claims 7 to 14~~ wherein the porcine fgl2 modulator is an antibody that binds to fgl2.

Claim 14 (currently amended): A ~~use~~-method according to ~~any one of claims 7 to 14~~ wherein the porcine fgl2 modulator is an antisense oligonucleotide that is complementary to the porcine fgl2 sequence.

Claim 15 (original): An isolated porcine fgl2 nucleic acid molecule having a nucleic acid sequence shown in Figure 1A (SEQ ID NO:1) or a homolog or analog thereof.

Claim 16 (currently amended): An isolated porcine fgl2 nucleic acid molecule according to claim ~~1 or 2~~-15 wherein the nucleic acid sequence comprises:

(a) a nucleic acid sequence as shown in Figure 1A (SEQ ID NO:1), wherein T can also be U;

- (b) a nucleic acid sequence that is complimentary to a nucleic acid sequence of (a);
- (c) a nucleic acid sequence that has substantial sequence homology to a nucleic acid sequence of (a) or (b);
- (d) a nucleic acid sequence that is an analog of a nucleic acid sequence of (a), (b) or (c); or
- (e) a nucleic acid sequence that hybridizes to a nucleic acid sequence of (a), (b), (c) or (d) under stringent hybridization conditions.

Claim 17 (original): An isolated porcine fgl2 protein having an amino acid sequence shown in Figure 1B (SEQ ID NO:2) or an analog, homolog or fragment thereof.

Claim 18 (original): An antibody that binds to an isolated protein according to claim 17.

Claim 19 (currently amended): An antisense oligonucleotide that is complementary to the porcine fgl2 sequence of claim 15 or 16.

Please renumber claim pages 49-51 as pages 63-65.